Rocket Pharmaceuticals plans to construct a new R & D and manufacturing facility in Cranbury, New Jersey.
The new facility is designed for the development of innovative gene therapy pipeline. The facility will be constructed with an area consisting of 103,720 ft2. In addition, it will also be used to support the pivotal trialsof the increasing pipeline ofLentivirus (LV) and Adeno-Associated Virus (AAV) gene therapies.
This new world-class R & D manufacturing facilityenables new capabilities towards bringingfive curative gene therapies to rare disease patients by 2025.
State of the Art R&D facilitywill support gene therapy capabilitiesby advancing multiple platforms and programs efficiently.
The one-half of the facility will be utilised for AAV Current Good Manufacturing Practice (cGMP) production whereas the second half includes R & D labs to support increasingpipeline and Quality Control (QC) laboratoriesto support CMC development for process and analytics.
After the construction of the new facility it is expected to create 150 new employees.